Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bryhali Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2008 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

NCT01111123
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%), Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

NCT01166646
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Proprionate Lotion 0.05%, Halobetasol Proprionate Cream 0.05%
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
San Diego, California • Clinton Township, Michigan • Troy, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

NCT04720105
View directory record Official record
Conditions
Palmoplantar Psoriasis, Plaque Psoriasis
Interventions
Duobrii®
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

NCT03992261
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Topical Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Hialeah, Florida • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

NCT02462083
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
46
States / cities
Mobile, Alabama • Beverly Hills, California • Encinitas, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

NCT02785172
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Vehicle Lotion, IDP-118 Vehicle Cream, IDP-118 Lotion, Ultravate Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
14
States / cities
Fullerton, California • La Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

NCT06042647
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

NCT05203315
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 6, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT03245385
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Treatment with Halobetasol propionate 0.05% topical spray
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 6, 2026, 5:19 AM EDT
Terminated Phase 3 Interventional Results available

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

NCT05608499
View directory record Official record
Conditions
Acne Keloidalis Nuchae, AKN
Interventions
Duobrii, Placebo, Bryhali
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

NCT00865605
View directory record Official record
Conditions
Healthy
Interventions
Halobetasol Propionate 0.05% Ointment, single exposure, Ultravate® 0.05% ointment, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02514577
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-122 Lotion, IDP-122 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Hot Springs, Arkansas • Encinitas, California • Encino, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

NCT02045277
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Encino, California • San Diego, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion, Ultravate Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
13
States / cities
Rogers, Arkansas • Beverly Hills, California • Carlsbad, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

NCT05282771
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02515097
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-122 Lotion, IDP-122 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Santa Ana, California • Boynton Beach, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis

NCT00990561
View directory record Official record
Conditions
Stable Plaque Psoriasis
Interventions
Ultravate ointment twice daily + LacHydrin lotion twice daily, Ultravate ointment once daily + LacHydrin lotion twice daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 6, 2026, 5:19 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis

NCT04571151
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LEXETTE 0.05% Topical Foam, Sorilux 0.005 % Topical Foam, Vehicle Foam
Drug · Other
Lead sponsor
Skin Sciences, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids

NCT05348200
View directory record Official record
Conditions
Hemorrhoids
Interventions
Monad 1, Monad 2, Monad 3, Combination - CITI-002 (low dose), Combination - CITI-002 (high dose)
Drug
Lead sponsor
Citius Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
16
States / cities
Huntsville, Alabama • Tucson, Arizona • Chula Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

NCT05872256
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
0.045% Tazarotene/0.01% Halobetasol Lotion
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

NCT00865267
View directory record Official record
Conditions
Healthy
Interventions
Ultravate® 0.05% ointment, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 6, 2026, 5:19 AM EDT